gdc
FDA Approvals, News & UpdatesGynecologic CancersNewsworthyOvarian Cancer

Lynparza Approved as Maintenance Treatment for Ovarian Cancer

In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
December 2017 Vol 3 No 6

Also on August 17, 2017, the FDA approved Lynparza (olaparib; from AstraZeneca) tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a complete or partial response to platinum-based chemotherapy.

On the same day, the FDA also approved a tablet form of Lynparza for patients with deleterious or suspected deleterious germline BRCA mutation–positive advanced ovarian cancer who have received 3 or more previous chemotherapies.

The most common side effects with Lynparza include anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, constipation, stomatitis, headache, dysgeusia, dyspepsia, decreased appetite, arthralgia, or myalgia.

Recommended For You
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Last modified: June 20, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country